Novavax stock today climbed roughly 11% in early U.S. trading after the vaccine developer delivered a decisive fourth-quarter earnings beat, swinging back to profitability and posting revenue well above Wall Street estimates. Shares traded near $10.59 shortly after the opening bell, extending gains as investors parsed the details behind the headline numbers.
The Gaithersburg, Maryland-based biotechnology company reported adjusted earnings per share of $0.11 for the fourth quarter, reversing expectations for a loss. Revenue rose to $147 million, up 67% from $88 million a year earlier and far ahead of consensus forecasts that had centered below $100 million.
The earnings surprise marked a notable shift in tone for a company that has spent the past two years restructuring operations and pivoting toward strategic licensing partnerships to stabilize its balance sheet.
Return to profitability reshapes narrative
Novavax posted net income of $18 million in the quarter, compared with a $81 million net loss in the prior-year period. The improvement reflects tighter operating discipline and milestone payments tied to key collaborations.
For the full year 2025, total revenue increased 65% year over year to approximately $1.1 billion. That performance was driven largely by $625 million in Nuvaxovid product sales and partnership-related revenue. The company reported full-year net income of $440 million, or $2.58 per share, and ended the year with $751 million in cash and equivalents.
Investors often focus on liquidity in mid-cap biotech names, and the strengthened cash position reduces near-term financing risk — a factor that has weighed heavily on vaccine developers in recent quarters.
Sanofi partnership boosts quarterly revenue
A significant contributor to the fourth-quarter result was Novavax’s collaboration with Sanofi. The company recorded $98 million in revenue from the Sanofi partnership during the quarter, contributing to $225 million in milestone payments for full-year 2025.
Partnership-driven revenue tends to be lumpy, and while it can create outsized quarterly beats, investors often discount it until a clearer cadence of milestone triggers emerges.
Pfizer licensing deal adds long-term optionality
In January 2026, Novavax entered into a licensing agreement with Pfizer covering its proprietary Matrix-M adjuvant platform. The agreement included a $30 million upfront payment and carries the potential for up to $500 million in additional milestone payments, along with high-mid single-digit royalty streams.
Licensing arrangements of this scale are often viewed as validation of platform technology, though markets typically wait for royalty revenue to materialize before assigning full valuation credit.
2026 revenue guidance resets expectations
Despite the strong quarter, Novavax’s forward outlook tempered enthusiasm. The company guided for 2026 adjusted total revenue of $230 million to $270 million, with a midpoint of $250 million. That represents a substantial decline from 2025’s reported revenue, reflecting the milestone-heavy nature of last year’s results.
Novavax expects combined research and development plus selling, general and administrative expenses of $380 million to $420 million. After accounting for $70 million to $80 million in anticipated R&D reimbursements, adjusted combined expenses are forecast at a midpoint of approximately $325 million.
The guidance underscores the company’s transition toward a leaner operating structure centered on platform monetization and partnership economics rather than large-scale standalone vaccine campaigns.
Market reaction reflects balance of optimism and caution
The stock’s double-digit gain suggests investors are rewarding the earnings beat and improved balance sheet. However, the scaled-back 2026 revenue forecast signals that 2025 benefited materially from milestone recognition that may not repeat at the same level.
In the current biotech environment, markets tend to prioritize visibility of recurring revenue over one-time partnership payments. As a result, Novavax’s valuation path from here is likely to hinge on the pace at which licensing deals translate into sustainable royalty streams and whether expense discipline continues.
With shares now stabilizing near the $10–$11 range, the debate shifts from whether the turnaround is credible — the latest quarter suggests progress — to whether partnership monetization can underpin durable growth.
